MX2020010815A - Biomarkers for graft-versus-host disease. - Google Patents

Biomarkers for graft-versus-host disease.

Info

Publication number
MX2020010815A
MX2020010815A MX2020010815A MX2020010815A MX2020010815A MX 2020010815 A MX2020010815 A MX 2020010815A MX 2020010815 A MX2020010815 A MX 2020010815A MX 2020010815 A MX2020010815 A MX 2020010815A MX 2020010815 A MX2020010815 A MX 2020010815A
Authority
MX
Mexico
Prior art keywords
biomarkers
versus
host disease
graft
subject
Prior art date
Application number
MX2020010815A
Other languages
Spanish (es)
Inventor
Hao Liu
Michael D Howell
Michael A Pratta
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2020010815A publication Critical patent/MX2020010815A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
MX2020010815A 2018-04-13 2019-04-11 Biomarkers for graft-versus-host disease. MX2020010815A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862657193P 2018-04-13 2018-04-13
US201862773308P 2018-11-30 2018-11-30
PCT/US2019/026884 WO2019200030A1 (en) 2018-04-13 2019-04-11 Biomarkers for graft-versus-host disease

Publications (1)

Publication Number Publication Date
MX2020010815A true MX2020010815A (en) 2020-12-11

Family

ID=66323933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010815A MX2020010815A (en) 2018-04-13 2019-04-11 Biomarkers for graft-versus-host disease.

Country Status (14)

Country Link
US (2) US11372003B2 (en)
EP (1) EP3775923A1 (en)
JP (1) JP7378420B2 (en)
KR (1) KR20210018218A (en)
CN (1) CN112567247A (en)
AU (1) AU2019252259A1 (en)
CA (1) CA3097025A1 (en)
IL (1) IL277955A (en)
MA (1) MA52208A (en)
MX (1) MX2020010815A (en)
PH (1) PH12020551683A1 (en)
SG (1) SG11202010092XA (en)
TW (1) TW202012935A (en)
WO (1) WO2019200030A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031882B1 (en) 2012-11-01 2019-03-29 Инсайт Холдингс Корпорейшн Tricyclic fused thiophene derivatives as jak inhibitors
MX2020008521A (en) 2018-02-16 2020-12-03 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders.
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN112567247A (en) * 2018-04-13 2021-03-26 因赛特公司 Biomarkers for graft versus host disease
KR20210109522A (en) 2018-10-31 2021-09-06 인사이트 코포레이션 Combination Therapy for Treatment of Blood Disorders
AU2020232757A1 (en) 2019-03-05 2021-10-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2021072098A1 (en) * 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (en) * 2019-10-10 2022-12-12 インサイト・コーポレイション Biomarkers for graft-versus-host disease
WO2021169017A1 (en) * 2020-02-25 2021-09-02 上海大学 Use of mesenchymal stem cells in treatment of severe covid-19 pneumonia
KR20230118118A (en) 2020-12-08 2023-08-10 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of vitiligo
KR102378996B1 (en) * 2021-01-13 2022-03-25 단국대학교 천안캠퍼스 산학협력단 Biomarker composition for predicting Odontogenic Differentiation of Dental Pulp Stem Cell

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US20040171068A1 (en) 2001-04-19 2004-09-02 Juergen Wehland Method for producing stable, regeneratable antibody arrays
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
PL2474545T3 (en) 2005-12-13 2017-04-28 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
HUE043732T2 (en) 2007-06-13 2019-09-30 Incyte Holdings Corp Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
ES2569528T3 (en) 2007-11-16 2016-05-11 Incyte Holdings Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as Janus kinase inhibitors
AU2009223640B2 (en) 2008-03-11 2013-07-04 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (en) 2009-10-09 2016-01-20 因西特控股公司 The hydroxy derivatives of 3-(4-(7H-pyrrolo-[2,3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl propionitrile, ketone group derivative and glucuronide
US8570829B2 (en) 2009-12-22 2013-10-29 Pgs Geophysical As Depth steerable seismic source array
EA023444B1 (en) 2010-02-18 2016-06-30 Инсайт Холдингс Корпорейшн Cyclobutane and methylcyclobutane derivatives, composition based thereon and methods of use thereof
AR081315A1 (en) 2010-03-10 2012-08-08 Incyte Corp HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
EA026201B1 (en) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PL2675451T3 (en) 2011-02-18 2016-05-31 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
AR086983A1 (en) 2011-06-20 2014-02-05 Incyte Corp DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
US20130115232A1 (en) * 2011-10-03 2013-05-09 Fred Hutchinson Cancer Research Center Methods for detecting graft-versus-host disease
DK3040336T3 (en) * 2012-03-02 2020-06-22 Sareum Ltd Compounds for use in the treatment of TYK2 Kinase-mediated conditions
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib
EA031882B1 (en) 2012-11-01 2019-03-29 Инсайт Холдингс Корпорейшн Tricyclic fused thiophene derivatives as jak inhibitors
PL2919766T3 (en) 2012-11-15 2021-10-04 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
FI3786162T3 (en) 2013-05-17 2023-10-02 Incyte Holdings Corp Bipyrazole derivatives as jak inhibitors
MX2016001639A (en) 2013-08-07 2016-10-07 Incyte Corp Sustained release dosage forms for a jak1 inhibitor.
EP3035966A1 (en) 2013-08-20 2016-06-29 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
HUE041456T2 (en) 2014-02-28 2019-05-28 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA201692193A1 (en) 2014-04-30 2017-07-31 Инсайт Корпорейшн METHODS OF OBTAINING JAK1 INHIBITOR AND ITS NEW FORMS
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10571478B2 (en) 2014-11-25 2020-02-25 Indiana University Research And Technology Corporation Biomarkers and assay to detect chronic graft versus host disease
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
DK3746429T3 (en) 2018-01-30 2022-05-02 Incyte Corp PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON)
MX2020008521A (en) 2018-02-16 2020-12-03 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders.
UA127925C2 (en) 2018-03-30 2024-02-14 Інсайт Корпорейшн Treatment of hidradenitis suppurativa using jak inhibitors
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN112567247A (en) 2018-04-13 2021-03-26 因赛特公司 Biomarkers for graft versus host disease
KR20210109522A (en) 2018-10-31 2021-09-06 인사이트 코포레이션 Combination Therapy for Treatment of Blood Disorders
JP2022514089A (en) 2018-12-19 2022-02-09 インサイト・コーポレイション JAK1 pathway inhibitor for the treatment of gastrointestinal disorders
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (en) 2019-10-10 2022-12-12 インサイト・コーポレイション Biomarkers for graft-versus-host disease

Also Published As

Publication number Publication date
JP7378420B2 (en) 2023-11-13
CN112567247A (en) 2021-03-26
JP2021521442A (en) 2021-08-26
US20230027606A1 (en) 2023-01-26
SG11202010092XA (en) 2020-11-27
CA3097025A1 (en) 2019-10-17
IL277955A (en) 2020-11-30
KR20210018218A (en) 2021-02-17
PH12020551683A1 (en) 2021-08-16
WO2019200030A1 (en) 2019-10-17
US20190331697A1 (en) 2019-10-31
AU2019252259A1 (en) 2020-12-03
TW202012935A (en) 2020-04-01
MA52208A (en) 2021-02-17
US11372003B2 (en) 2022-06-28
EP3775923A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
MX2021009682A (en) Cyclin-dependent kinase 2 biomarkers and uses thereof.
CR20190350A (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFß1 INHIBITORS AND USE THEREOF
WO2020191041A3 (en) Biomarkers for vitiligo
EA201890382A1 (en) ANTIBODY CONSTRUCTIONS FOR CD70 AND CD3
MX2020010947A (en) Methods of treating alzheimer's disease.
EA200900177A1 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF THEIR APPLICATION
MX2022008100A (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions.
FR3021970B1 (en) ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES
MX2017015922A (en) Biomarkers associated with lsd1 inhibitors and uses thereof.
EA201792641A1 (en) IGFBP3 / TMEM219 AXIS INHIBITOR AND DIABETES
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA201890728A3 (en) TREATMENT OF NTCP ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND DISEASES ASSOCIATED WITH NRLP3-INFLAMMASOMA INHIBITORS
EA201790563A8 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
WO2020104705A3 (en) Predicting a treatment response in inflammatory bowel disease
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
MX2020006388A (en) Biomarkers for diagnosis and prognosis of corneal ectatic disorders.
MX2021002652A (en) Use of casein kinase 1 inhibitors for treating vascular diseases.
WO2015036643A3 (en) Marker for predicting metastasis of breast cancer
MX2009011388A (en) Polymerase inhibitors and the use thereof for the treatment of tumors.
MX2017014540A (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus.
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
EA201790093A1 (en) HEPATOCELLULAR CARCINOMA THERAPY
EA202190504A1 (en) METHODS FOR TREATMENT OF PSORIASIS
EA201990509A1 (en) USE OF LYSYLOXIDASE-SIMILAR PROTEIN 2 INHIBITOR